Zevra Therapeutics Statistics
Want to see ZVRA full AI Analyst Report?
Zevra Therapeutics (ZVRA) Stock Statistics & Valuation Metrics
Total Valuation
Zevra Therapeutics has a market cap or net worth of $550.42M. The enterprise value is $482.86M.
- Market Cap
- $550.42M
- Enterprise Value
- $482.86M
Share Statistics
Zevra Therapeutics has 59,504,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 59,504,620
- Owned by Insiders
- 1.46%
- Owned by Institutions
- 66.25%
Financial Efficiency
Zevra Therapeutics’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -1.65%.
- Return on Equity (ROE)
- 0.54
- Return on Assets (ROA)
- 0.29
- Return on Invested Capital (ROIC)
- -1.65%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 1.75M
- Profits Per Employee
- 1.36M
- Employee Count
- 61
- Asset Turnover
- 0.37
- Inventory Turnover
- 9.47
Valuation Ratios
The current PE Ratio of Zevra Therapeutics is 7.24. Zevra Therapeutics’s PEG ratio is 0.07.
- PE Ratio
- 7.24
- PS Ratio
- 3.73
- PB Ratio
- 2.31
- Price to FCF
- 14.41
- Price to Operating Cash Flow
- 14.22
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 106.47M and earned 83.23M in profits. Earnings per share was 1.40.
- Revenue
- 106.47M
- Gross Profit
- 89.99M
- Operating Income
- -4.23M
- Pretax Income
- 86.68M
- Net Income
- 83.23M
- EBITDA
- 98.71M
- Earnings Per Share (EPS)
- 1.40
Cash Flow
In the last 12 months, operating cash flow was 38.74M and capital expenditures -459,000, giving a free cash flow of 38.28M billion.
- Operating Cash Flow
- 38.74M
- Free Cash Flow
- 38.28M
- Free Cash Flow per Share
- 0.64
Dividends & Yields
Zevra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.84%
- Earnings Yield
- 13.97%
Stock Price Statistics
- Beta
- 0.78
- 52-Week Price Change
- 2.40%
- 50-Day Moving Average
- 10.99
- 200-Day Moving Average
- 10.89
- Relative Strength Index (RSI)
- 38.37
- Average Volume (3m)
- 956.75K
Important Dates
Zevra Therapeutics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Zevra Therapeutics as a current ratio of 5.68, with Debt / Equity ratio of 40.87%
- Current Ratio
- 5.68
- Quick Ratio
- 5.63
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- 0.01
- Interest Coverage Ratio
- -0.53
Taxes
In the past 12 months, Zevra Therapeutics has paid 3.45M in taxes.
- Income Tax
- 3.45M
- Effective Tax Rate
- 0.04
Enterprise Valuation
Zevra Therapeutics EV to EBITDA ratio is 4.78, with an EV/FCF ratio of 11.45.
- EV to Sales
- 2.97
- EV to EBITDA
- 4.78
- EV to Free Cash Flow
- 11.45
- EV to Operating Cash Flow
- 11.32
Balance Sheet
Zevra Therapeutics has $195.57M in cash and marketable securities with $1.23M in debt, giving a net cash position of $194.34M billion.
- Cash & Marketable Securities
- $195.57M
- Total Debt
- $1.23M
- Net Cash
- $194.34M
- Net Cash Per Share
- $3.27
- Tangible Book Value Per Share
- $3.85
Margins
Gross margin is 95.19%, with operating margin of 31.47%, and net profit margin of 52.80%.
- Gross Margin
- 95.19%
- Operating Margin
- 31.47%
- Pretax Margin
- 60.90%
- Net Profit Margin
- 52.80%
- EBITDA Margin
- 62.01%
- EBIT Margin
- 61.06%
Analyst Forecast
The average price target for Zevra Therapeutics is $24.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $24.67
- Price Target Upside
- 162.41% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 75.10%
- EPS Growth Forecast
- 103.22%
Scores
- Smart Score
- 9
- AI Score
- 73

